Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 3/2019

01.11.2018 | Review

A systematic review of interventions to improve adherence to endocrine therapy

verfasst von: Sue P. Heiney, Pearman D. Parker, Tisha M. Felder, Swann Arp Adams, Omonefe O. Omofuma, Jennifer M Hulett

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Adherence to endocrine therapy for hormone positive breast cancer is a significant problem, especially in minority populations. Further, endocrine therapy reduces recurrence and thus mortality. However, little data are available on interventions to improve adherence. The authors conducted a systematic review to examine the impact of interventions, strategies, or approaches aimed to improve endocrine therapy adherence among women with breast cancer. A secondary aim was to determine if interventions had any cultural modifications.

Methods

Two of the authors examined articles published between 2006 and 2017 from a wide variety of databases using Covidence systematic review platform.

Results

In total, 16 eligible studies met criteria for review including 4 randomized controlled trials, 4 retrospective studies, and 8 with various observational designs. Eligible studies used a broad range of definitions for adherence and measured adherence by self-report, medical records, claims data, and combinations of these. All used 80% medication possession ratio as a standard for adherence. Patient information/education was the most frequent intervention strategy but did not demonstrate a significant effect except in one study. Significant results were noted when education was combined with communication strategies.

Conclusions

Researchers need a standard definition for adherence and a reliable measure that is feasible to use in a variety of studies. While education may be a necessary component of an intervention, when used alone, it is not a sufficient approach to change behavior.
Literatur
1.
Early Breast Cancer Clinical Trialsists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365(9472):1687–1717CrossRef
2.
Fontein DBY, Nortier JWR, Liefers GJ et al (2012) High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. EJSO 38(2):110–117PubMedCrossRef
3.
Kesmodel SB, Goloubeva OG, Rosenblatt PY et al (2018) Patient-reported adherence to adjuvant aromatase inhibitor therapy using the Morisky Medication Adherence Scale: an evaluation of predictors. Am J Clin Oncol 41(5):508–512PubMedCrossRef
4.
Kimmick G, Edmond SN, Bosworth HB et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast 24(5):630–636PubMedPubMedCentralCrossRef
5.
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524PubMedPubMedCentralCrossRef
6.
Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445–3451PubMedPubMedCentralCrossRef
7.
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562PubMedCrossRef
8.
Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606PubMedCrossRef
9.
Wheeler SB, Kohler RE, Reeder-Hayes KE et al (2014) Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv 8(4):603–610PubMedPubMedCentralCrossRef
10.
Gotay C, Dunn J (2011) Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res 11(6):709–715PubMedCrossRef
11.
Wu J, Stafkey-Mailey D, Bennett CL (2012) Long-term adherence to hormone therapy in medicaid-enrolled women with breast cancer. Health Outcomes Res Med 3(4):e195–e203CrossRef
12.
Yung RL, Hassett MJ, Chen K et al (2012) Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst 104(14):1102–1105PubMedPubMedCentralCrossRef
13.
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Br Cancer Res Treat 134(2):459–478CrossRef
14.
McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768PubMedPubMedCentralCrossRef
15.
Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedPubMedCentralCrossRef
16.
Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid 1(4):E1–E25CrossRef
17.
Chlebowski RT, Kim J, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res 7(4):378–387CrossRef
18.
Ursem CJ, Bosworth HB, Shelby RA, Hwang W, Anderson RT, Kimmick GG (2015) Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. J Womens Health 24(5):403–408CrossRef
19.
Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI (2015) Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol 33(9):1053–1059PubMedPubMedCentralCrossRef
20.
Farias AJ, Du XL (2017) Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol 35(1):86–95PubMedCrossRef
21.
Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRef
22.
Sheppard VB, Wallington SF, Willey SC et al (2013) A peer-led decision support intervention improves decision outcomes in black women with breast cancer. J Cancer Educ 28(2):262–269PubMedPubMedCentralCrossRef
23.
Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986–993PubMedPubMedCentralCrossRef
24.
Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 11:305–322PubMedPubMedCentralCrossRef
25.
Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. Patient Educ Couns 98(12):1524–1539CrossRef
26.
Van Liew J, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531PubMedCrossRef
27.
McCarthy AM, Armstrong K, Yang J (2015) Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. Am J Public Health 105(Suppl(3):S446–S448PubMedPubMedCentralCrossRef
28.
Reeder-Hayes KE, Meyer AM, Dusetzina SB, Liu H, Wheeler SB (2014) Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat 145(3):743–751PubMedPubMedCentralCrossRef
29.
30.
von Elm E, Altman DG, Egger M et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349CrossRef
31.
Chad-Friedman E, Coleman S, Traeger LN et al (2017) Psychological distress associated with cancer screening: a systematic review. Cancer 123(20):3882–3894PubMedCrossRef
32.
Markopoulos C, Neven P, Tanner M et al (2015) Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future Oncol 11(2):205–217PubMedCrossRef
33.
Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 23(4):393–399PubMedCrossRef
34.
Jacob L, Hadji P, Albert US, Kalder M, Kostev K (2015) Impact of disease management programs on women with breast cancer in Germany. Breast Cancer Res Treat 153(2):391–395PubMedCrossRef
35.
Kostev K, May U, Hog D et al (2013) Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany. Int J Clin Pharmacol Ther 51(12):969–975PubMedCrossRef
36.
Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29(18):2534–2542PubMedPubMedCentralCrossRef
37.
Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836PubMedCrossRef
38.
Arriola KRJ, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103CrossRef
39.
Yu KD, Zhou Y, Liu GY et al (2012) A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 134(1):307–313PubMedCrossRef
40.
Hadji P, Blettner M, Harbeck N et al (2013) The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24(6):1505–1512PubMedCrossRef
41.
Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. BMC Cancer 13(1):1–9CrossRef
42.
Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRef
43.
Heisig SR, Shedden-Mora MC, von Blanckenburg P et al (2015) Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology 24(2):130–137PubMedCrossRef
44.
Lin JJ, Chao J, Bickell NA, Wisnivesky JP (2017) Patient-provider communication and hormonal therapy side effects in breast cancer survivors. Women Health 57(8):976–989PubMedCrossRef
45.
46.
Castaldi M, Safadjou S, Elrafei T, McNelis J (2017) A multidisciplinary patient navigation program improves compliance with adjuvant breast cancer therapy in a public hospital. Am J Med Qual 32(4):406–413PubMedCrossRef
47.
Albert US, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care 6(3):221–226PubMedPubMedCentralCrossRef
48.
Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436PubMedCrossRef
49.
Wing RR (2000) Cross-cutting themes in maintenance of behavior change. Health Psychol 19(1S):84–88PubMedCrossRef
50.
Hurtado-de-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB (2016) Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review. Clin Breast Cancer 16(4):247–255PubMedPubMedCentralCrossRef
51.
Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L (2013) Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence 7:675–682PubMedPubMedCentralCrossRef
52.
Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr (2011) Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol 64(3):250–254PubMedCrossRef
53.
Sutton S, Kinmonth A-L, Hardeman W et al (2014) Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity. Ann Behav Med 48(3):293–299PubMedPubMedCentralCrossRef
54.
Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42(7):649–652PubMedCrossRef
55.
Tre-Hardy M, Capron A, Antunes MV, Linden R, Wallemacq P (2016) Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level LC-MS/MS system. Clin Biochem 49(16–17):1295–1298PubMedCrossRef
56.
Rothman AJ (2000) Toward a theory-based analysis of behavioral maintenance. Health Psychol 19(1, Suppl):64–69PubMedCrossRef
57.
Given B, Given C, Sikorskii A (2007) Deconstruction of a nursing intervention to examine the mechanism of action. Oncol Nurs Forum 34(1):199
58.
Song M-K, Ward SE (2015) Making visible a theory-guided advance care planning intervention. J Nurs Scholarsh 47(5):389–396PubMed
59.
Irwin M (2015) Theoretical foundations of adherence behaviors: synthesis and application in adherence to oral oncology agents. Clin J Oncol Nur 19(3 Suppl):31–35CrossRef
60.
Manning M, Bettencourt A (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health 26(9):1173–1187PubMedCrossRef
61.
Latter S, Sibley A, Skinner TC et al (2010) The impact of an intervention for nurse prescribers on consultations to promote patient medicine-taking in diabetes: a mixed methods study. Int J Nurs Stud 47(9):1126–1138PubMedCrossRef
62.
World Health Organization (2003) Adherence to long-term therapies: evidence for action. Geneva, Switzerland
63.
Gearing RE, El-Bassel N, Ghesquiere A, Baldwin S, Gillies J, Ngeow E (2011) Major ingredients of fidelity: a review and scientific guide to improving quality of intervention research implementation. Clin Psychol Rev 31(1):79–88PubMedCrossRef
64.
Bellg AJ, Borrelli B, Resnick B et al (2004) Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychol 23(5):443–451PubMedCrossRef
65.
66.
Kearney MH, Simonelli MC (2006) Intervention fidelity: lessons learned from an unsuccessful pilot study. Appl Nurs Res 19(3):163–166PubMedCrossRef
67.
Airhihenbuwa CO, Ford CL, Iwelunmor JI (2014) Why culture matters in health interventions: lessons from HIV/AIDS stigma and NCDs. Health Educ Behav 41(1):78–84PubMedCrossRef
68.
Fisher TL, Burnet DL, Huang ES, Chin MH, Cagney KA (2007) Cultural leverage: interventions using culture to narrow racial disparities in health care. Med Care Res Rev 64(5 Suppl):243S–282SPubMedPubMedCentralCrossRef
69.
Hamilton JB, Agarwal M, Song L, Moore MAD, Best N (2011) Are psychosocial interventions targeting older African American cancer survivors culturally appropriate? A review of the literature. Cancer Nurs 35(2):E12–E23CrossRef
70.
Jeffe D, Perez M, Yan Y et al (2015) African American breast cancer survivor stories: trial usage of a cancer-communication video program. Ann Behav Med 49(Suppl 1):s5
71.
Baezconde-Garbanati LA, Chatterjee JS, Frank LB et al (2014) Tamale Lesson: a case study of a narrative health communication intervention. J Commun Healthc 7(2):82–92CrossRef
72.
Champion VL, Springston JK, Zollinger TW et al (2006) Comparison of three interventions to increase mammography screening in low income African American women. Cancer Detect Prev 30(6):535–544PubMedCrossRef
73.
Heiney SP, Adams SA, Khang L (2014) Agreement between patient self-report and an objective measure of treatment among African American women with breast cancer. J Oncol Navig Surviv 5(3):21–27
74.
Felder TM, Palmer NR, Lal LS, Mullen PD (2011) What is the evidence for pharmaceutical patient assistance programs? A systematic review. J Health Care Poor Underserved 22(1):24–49PubMedPubMedCentral
75.
Amaro H, Morrill AC, Dai J, Cabral H, Raj A (2005) Heterosexual behavioral maintenance and change following HIV counseling and testing. Health Psychol 10(2):287–300CrossRef
76.
Amico KR, Barta W, Konkle-Parker DJ et al (2009) The information–motivation–behavioral skills model of ART adherence in a Deep South HIV + clinic sample. AIDS Behav 13:66–75PubMedCrossRef
77.
Starace F, Massa A, Amico KR, Fisher JD (2006) Adherence to antiretroviral therapy: an empirical test of the information-motivation-behavioral skills model. Health Psychol 25(2):153–162PubMedCrossRef
Metadaten
Titel
A systematic review of interventions to improve adherence to endocrine therapy
verfasst von
Sue P. Heiney
Pearman D. Parker
Tisha M. Felder
Swann Arp Adams
Omonefe O. Omofuma
Jennifer M Hulett
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5012-7

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Clinical trial

YouTube English videos as a source of information on breast self-examination

Preclinical study

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth

Brief Report

Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy

Epidemiology

Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®

Epidemiology

Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women

Epidemiology

Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise